Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab was written by Van der Moeren, Nathalie;Selhorst, Philippe;Ha, My;Heireman, Laura;Van Gaal, Pieter-Jan;Breems, Dimitri;Meysman, Pieter;Laukens, Kris;Verstrepen, Walter;Van Gasse, Natasja;Ogunjimi, Benson;Arien, Kevin K.;Naesens, Reinout. And the article was included in Viruses in 2022.Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:
Prolonged shedding of SARS-CoV-2 in immunocompromised patients has been described. Furthermore, an accumulation of mutations of the SARS-CoV-2 genome in these patients has been observed We describe the viral evolution, immunol. response and clin. course of a patient with a lymphoma in complete remission who had received therapy with rituximab and remained SARS-CoV-2 RT-qPCR pos. for 161 days. The patient remained hospitalised for 10 days, after which he fully recovered and remained asymptomatic. A progressive increase in Ct-value, coinciding with a progressive rise in lymphocyte count, was seen from day 137 onward. Culture of a nasopharyngeal swab on day 67 showed growth of SARS-CoV-2. Whole genome sequencing (WGS) demonstrated that the virus belonged to the wildtype SARS-CoV-2 clade 20B/GR, but rapidly accumulated a high number of mutations as well as deletions in the N-terminal domain of its spike protein. SARS-CoV-2 persistence in immunocompromised individuals has important clin. implications, but halting immunosuppressive therapy might result in a favorable clin. course. The long-term shedding of viable virus necessitates customized infection prevention measures in these individuals. The observed accelerated accumulation of mutations of the SARS-CoV-2 genome in these patients might facilitate the origin of new VOCs that might subsequently spread in the general community. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Formula: C16H21Cl2N3O2).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Formula: C16H21Cl2N3O2
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem